Outcome of the Board Meeting held on 01.08.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts less than Nifty Microcap 250 and 5.4 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved audited standalone and consolidated financial results for the half year and year ended 31 March 2025. Standalone revenue from operations crashed from ₹855.79 lakhs in FY24 to just ₹112.74 lakhs in FY25, a drop of roughly 87%. Standalone swung from a small profit of ₹5.11 lakhs last year to a net loss of ₹265.95 lakhs this year, with EPS at ₹(4.21). On a consolidated basis, revenue fell from ₹972.29 lakhs to ₹196.36 lakhs (~80% decline) and net loss widened to ₹477.49 lakhs from ₹231.59 lakhs. The auditor (M/s Mathesh & Ramana) gave an unmodified and unqualified opinion on both sets of results. Filing was delayed because the company could not get accounts from an associate in time. Consolidated subsidiaries (Vanta Clinical Research, CEBIS) reported heavy losses of about ₹1,063 lakhs for FY25, eroding subsidiary equity into negative territory.
This is a clearly negative filing — revenues have collapsed and losses have deepened sharply, with the group also posting negative operating cash flow of ₹240.86 lakhs and consolidated borrowings around ₹7,000 lakhs against total equity of just ₹378 lakhs, pointing to significant financial stress. Shareholders should view this as a serious red flag on business performance and balance sheet health, though the unqualified auditor opinion and absence of any reported loan default limit immediate solvency concerns.